Clinical Trials
2 trialsNCT07612007 2026-06-01
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
Mayo Clinic
Phase 2 Not yet recruiting
NCT00028626 2013-06-05
Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed